Financial News Feed

Stronger Sell Today ADMS ranks #4072 as SELL CANDIDATE. Weaker Sell
Today ADMS ranks #4072 as SELL CANDIDATE.

ADMS stock Adamas Pharmaceuticals

ADMS stock
Adamas Pharmaceuticals

Checking in on shares of Adamas Pharma (ADMS), we can see that the current opinion signal on the stock for today’s session is 40% Sell. Looking back at the last month, the opinion signal reads 88% S...

Read more

HC Wainwright set a $40.00 price target on Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note issued to investors on Monday. The brokerage currently has a buy rating on the specialty pharmaceutic...

Read more

The Aroon Oscillator has reached a key pivot point for Adamas Pharma (ADMS) as the upward trend for the shares continues to build. Whether or not this can continue can be determined by looking at seve...

Read more

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has recently been spotted approaching 52-week highs. Investors may be following how the stock price reacts as it nears this level. At the time of writing, co...

Read more

Investors following shares of Adamas Pharma (ADMS) may have seen that the stock has slid -8.02% over the last 4 weeks. Looking out over the last half-year, shares have seen a change of -68.15%. Watchi...

Read more

Adamas Pharmaceuticals (ADMS) Shares Down 5.1%
10:48am, Wednesday, 16'th Jan 2019
Adamas Pharmaceuticals Inc (NASDAQ:ADMS) dropped 5.1% during trading on Monday . The company traded as low as $8.73 and last traded at $8.75. Approximately 547,789 shares traded hands during trading, ...

Read more

Focusing in on shares of Adamas Pharma (ADMS), we can see that the Kaufman Adaptive Moving Average has been trending lower over the previous five days. Traders may be watching the KAMA to identify pos...

Read more

Adamas Pharmaceuticals (NASDAQ:ADMS) received a $40.00 price objective from equities researchers at HC Wainwright in a report released on Monday. The brokerage currently has a “buy” rating on the ...

Read more

Wall Street analysts forecast that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will announce $13.30 million in sales for the current quarter, according to Zacks. Two analysts have made estimates for Adam...

Read more

Adamas Pharma (ADMS) shares are being closely watched by investors as the Twiggs Money Flow indicator has dipped below the zero line. This typically indicates that further downward pressure is ahead f...

Read more

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Ratings Coverage Among 4 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Adamas Pha...

Read more

Mizuho restated their hold rating on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note issued to investors on Friday morning. The firm currently has a $11.00 price target on the specia...

Read more

Zacks Investment Research cut shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a sell rating in a research note published on Monday. According to Zacks, “Adamas Pharmaceuticals, ...

Read more

Zacks Investment Research lowered shares of Adamas Pharmaceuticals (NASDAQ:ADMS) from a hold rating to a sell rating in a research report report published on Monday. According to Zacks, “Adamas Phar...

Read more

Adamas Pharmaceuticals Inc. (ADMS) had a rough trading day for Monday January 14 as shares tumbled 5.1%, or a loss of $-0.47 per share, to close at $8.75. After opening the day at $9.11, shares of...

Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank